Human papillomavirus-associated oropharyngeal cancer: Defining risk groups and clinical trials

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3243-3250

  Bhatia, Aarti ^a   Burtness, Barbara ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CISPLATIN; PROTEIN P16; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HIGH RISK POPULATION; HUMAN; OROPHARYNX CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; SURGICAL TECHNIQUE; WART VIRUS; AGE; CARCINOMA, SQUAMOUS CELL; COMPLICATION; HEAD AND NECK NEOPLASMS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; RISK FACTOR; VIROLOGY;

AGE FACTORS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS;

EID: 84944222541     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.2358     Document Type: Review

References (67)

1. Sturgis EM, Ang KK: The epidemic of HPVassociated oropharyngeal cancer is here: Is it time to change our treatment paradigms? J Natl Compr Canc Netw 9: 665-673, 2011
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301, 2011
3. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420, 2008
4. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000
5. Mehanna H, Beech T, Nicholson T, et al: Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: Systematic review and meta-analysis of trends by time and region. Head Neck 35: 747-755, 2013
6. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31: 4550-4559, 2013
7. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010
8. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomaviruspositive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008
9. Huang SH, O'Sullivan B, Xu W, et al: Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys 87: 1078-1085, 2013
10. Lorch JH, Goloubeva O, Haddad RI, et al: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12: 153-159, 2011
11. Nguyen-Tan PF, Zhang Q, Ang KK, et al: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Longterm report of efficacy and toxicity. J Clin Oncol 32: 3858-3867, 2014
12. Posner MR, Lorch JH, Goloubeva O, et al: Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 22: 1071-1077, 2011
13. Reference deleted
14. Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28: 4142-4148, 2010
15. Vermorken JB, Psyrri A, Mesia R, et al: Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase III EXTREME trial. Ann Oncol 25: 801-807, 2014
16. Lassen P, Eriksen JG, Krogdahl A, et al: The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6& 7 trial. Radiother Oncol 100: 49-55, 2011
17. Slebos RJ, Yi Y, Ely K, et al: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12: 701-709, 2006
18. O'Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31: 543-550, 2013
19. Fakhry C, Zhang Q, Nguyen-Tan PF, et al: Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32: 3365-3373, 2014
20. Ang KK, Zhang Q, Rosenthal DI, et al: Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32: 2940-2950, 2014
21. Steinau M, Saraiya M, Goodman MT, et al: Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 20: 822-828, 2014
22. Nichols AC, Palma DA, Dhaliwal SS, et al: The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol 20: 212-219, 2013
23. Maier M, Kraft K, Steinestel K, et al: Human papillomavirus in squamous cell cancer of the head and neck: A study at the Ulm Military Hospital, Germany [in German]. HNO 61: 593-601, 2013
24. Quintero K, Giraldo GA, Uribe ML, et al: Human papillomavirus types in cases of squamous cell carcinoma of head and neck in Colombia. Braz J Otorhinolaryngol 79: 375-381, 2013
25. St Guily JL, Jacquard AC, Pretet JL, et al: Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France: The EDiTH VI study. J Clin Virol 51: 100-104, 2011
26. Deng Z, Hasegawa M, Matayoshi S, et al: Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol 268: 1625-1631, 2011
27. Hong AM, Grulich AE, Jones D, et al: Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 28: 3269-3272, 2010
28. Baboci L, Boscolo-Rizzo P, Holzinger D, et al: Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J 10: 334, 2013
29. Snow AN, Laudadio J: Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol 17: 394-403, 2010
30. do Sacramento PR, Babeto E, Colombo J, et al: The prevalence of human papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J Med Virol 78: 614-618, 2006
31. Schache AG, Liloglou T, Risk JM, et al: Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: Sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17: 6262-6271, 2011
32. Badaracco G, Rizzo C, Mafera B, et al: Molecular analyses and prognostic relevance of HPV in head and neck tumours. Oncol Rep 17: 931-939, 2007
33. Venuti A, Paolini F: HPV detection methods in head and neck cancer. Head Neck Pathol 6: S63-S74, 2012 (suppl 1)
34. Klussmann JP, Gultekin E, Weissenborn SJ, et al: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753, 2003
35. Adelstein DJ, Ridge JA, Gillison ML, et al: Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 31: 1393- 1422, 2009
36. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990
37. Munger K, Basile JR, Duensing S, et al: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898, 2001
38. Weinberger PM, Yu Z, Haffty BG, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24: 736-747, 2006
39. Weinberger PM, Yu Z, Kountourakis P, et al: Defining molecular phenotypes of human papillomavirusassociated oropharyngeal squamous cell carcinoma: Validation of three-class hypothesis. Otolaryngol Head Neck Surg 141: 382-389, 2009
40. Chung CH, Zhang Q, Hammond EM, et al: Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 81: 331-338, 2011
41. Pectasides E, Rampias T, Kountourakis P, et al: Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 17: 2947-2954, 2011
42. Young RJ, Rischin D, Fisher R, et al: Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 20: 1230-1237, 2011
43. Husain H, Psyrri A, Markovic A, et al: Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope 122: 2762-2768, 2012
44. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005
45. Licitra L, Mesia R, Rivera F, et al: Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22: 1078-1087, 2011
46. Bessman NJ, Bagchi A, Ferguson KM, et al: Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. Cell Rep 9: 1306-1317, 2014
47. Rampias T, Pectasides E, Prasad M, et al: Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol 24: 2124-2131, 2013
48. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28: 2989-2995, 2010
49. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362: 933-940, 2003
50. Reference deleted
51. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28, 2010
52. Rosenthal DI, Harari PM, Giralt J, et al: Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 32: 384s, 2014 (abstr 6001)
53. Argiris A, Li S, Ghebremichael M, et al: Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: An analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 25: 1410-1416, 2014
54. Maxwell JH, Kumar B, Feng FY, et al: Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 16: 1226-1235, 2010
55. Gillison ML, Zhang Q, Jordan R, et al: Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30: 2102-2111, 2012
56. Wei L, Griego AM, Chu M, et al: Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis 35: 2373-2381, 2014
57. Huang SH, Xu W, Waldron J, et al: Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33: 836-845, 2015
58. Nguyen NP, Sallah S, Karlsson U, et al: Combined chemotherapy and radiation therapy for head and neck malignancies: Quality of life issues. Cancer 94: 1131-1141, 2002
59. Sinard RJ, Tobin EJ, Mazzaferri EL, et al: Hypothyroidism after treatment for nonthyroid head and neck cancer. Arch Otolaryngol Head Neck Surg 126: 652-657, 2000
60. Gupta AK, Lee JH, Wilke WW, et al: Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 74: 928-933, 2009
61. Kimple RJ, Smith MA, Blitzer GC, et al: Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 73: 4791-4800, 2013
62. Rieckmann T, Tribius S, Grob TJ, et al: HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 107: 242-246, 2013
63. Cmelak A, Li S, Marur S, et al: E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol 32: 385s, 2014 (abstr LBA6006)
64. Cmelak AJ, Li S, Murphy B, et al: Locally advanced resectable larynx (L) or oropharynx (OP) cancer: Updated results of organ preservation trial ECOG 2399. J Clin Oncol 24: 286s, 2006 (abstr 5527)
65. Lui VW, Hedberg ML, Li H, et al: Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3: 761-769, 2013
66. Burtness B, Lee J-W, Yang D, et al: Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. J Clin Oncol 31: 369s, 2013 (abstr 6028)
67. Byers LA, Diao L, Shing Ng PK, et al: Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy. J Clin Oncol 32: 391s, 2014 (abstr 6030)